Aptamer?I think I mentioned this once before. What is an aptamer vs a vaccine?
GUELPH, ON / ACCESSWIRE / December 13, 2023 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property technology development and commercialization company announces the launch of Triera Biosciences Ltd. (Triera) as Zentek's wholly owned subsidiary for its aptamer platform technology. As announced in the October 5th, 2023, news release, this subsidiary now owns the exclusive, global licensing rights for all aptamer-based technology from the collaboration with McMaster University.
The Company is taking this action following the strong, consistent pre-clinical results of its universal aptamer as a treatment against the SARS-CoV-2 virus including the latest Omicron XBB 1.5 variant and will continue to build upon its previous work on a rapid detection platform within the new subsidiary. Triera will offer a pure play in the biotech space when operated as an independent business and be more accessible to potential pharmaceutical partners, funders, and other interested parties.
"The aptamer platform technology has quickly evolved into a strong differentiated value creator for Zentek and its investors. By launching Triera Biosciences, we are creating a standalone company with a clear, concise, differentiated value proposition that will appeal directly to the biotech ecosystem" said Greg Fenton, CEO of Zentek. "With the launch of Triera we have begun outreach to potential partners and collaborators as we continue to build on our current pre-clinical results and develop our team."
The Company is launching a new website: Triera.ca where investors and stakeholders can review the latest developments of the aptamer platform technology.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.